JP Morgan Healthcare Conference, January 2019; Optio Biopharma Solutions conducts neurodegenerative rare disease asset valuation due diligence and other activities

JPM, January 2019, San Francisco. In addition to attending JPM meetings with a focus on rare disease, Optio conducted asset valuation work on behalf of a client. Discussions with a potential out-licensing partner were held to reach an understanding on market assumptions. Optio provided due diligence through interviews with relevant thought leaders combined with expert opinion on valuation and commercial risk.



Leave a Reply